Clinical trial
EPO-BUL-01 - Study of the Optimization of Anemia Management of EPREX (Epoetin…
NCT00338000 · Janssen Pharmaceutica N.V., Belgium, Industry · Completed
Key facts
| NCT number | NCT00338000 |
|---|---|
| Title | EPO-BUL-01 - Study of the Optimization of Anemia Management of EPREX (Epoetin Alfa) in Predialysis Patients With Chronic Renal Failure |
| Official title | An Open-Label Study of the Optimization of Anemia Management of EPREX (Epoetin Alfa) in Predialysis Patients With Chronic Renal Failure |
| Lead sponsor | Janssen Pharmaceutica N.V., Belgium, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Chronic Renal Failure |
| Intervention type | Drug |
| Interventions | Epoetin alfa |
| Enrollment | 292 |
| Start date | Jun 1, 2001 |
| Completion | May 1, 2005 |
| First posted | Jun 20, 2006 |
| Last update posted | Feb 1, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: